Media stories about Exactech (NASDAQ:EXAC) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Exactech earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 46.6360972130564 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
Shares of Exactech (EXAC) remained flat at $41.85 during trading on Friday. The company’s stock had a trading volume of 554,416 shares. Exactech has a one year low of $22.20 and a one year high of $42.55. The stock has a market capitalization of $600.46 million, a price-to-earnings ratio of 804.81 and a beta of 1.01. The firm has a 50 day moving average of $32.78 and a 200 day moving average of $30.48.
Exactech (NASDAQ:EXAC) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.33. Exactech had a net margin of 0.30% and a return on equity of 7.39%. The company had revenue of $67.30 million for the quarter, compared to the consensus estimate of $67.75 million. During the same quarter in the prior year, the company earned $0.31 EPS. Exactech’s quarterly revenue was up 1.8% on a year-over-year basis. On average, equities research analysts forecast that Exactech will post $1.30 EPS for the current year.
Several research firms have weighed in on EXAC. Zacks Investment Research cut shares of Exactech from a “hold” rating to a “sell” rating in a report on Wednesday. Gabelli cut shares of Exactech from a “buy” rating to a “hold” rating in a report on Tuesday. Robert W. Baird set a $34.00 target price on shares of Exactech and gave the stock a “buy” rating in a report on Sunday, October 15th. Sidoti cut shares of Exactech from a “buy” rating to a “neutral” rating in a report on Monday. Finally, BidaskClub upgraded shares of Exactech from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $42.00.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/27/exactech-exac-earns-coverage-optimism-score-of-0-09.html.
In other news, Director Fern Watts sold 1,013 shares of the stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $29.04, for a total transaction of $29,417.52. Following the transaction, the director now owns 4,727 shares in the company, valued at approximately $137,272.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 28.30% of the company’s stock.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.